Abcellera Biologics Inc (ABCL) — Cash Flow Reinvestment Rate

Latest as of June 2023: 1.89x

Abcellera Biologics Inc (ABCL) has a Cash Flow Reinvestment Rate of 1.89x as of June 2023, reinvesting $37.52 Million (capex $27.35 Million plus investments $-10.17 Million) from operating cash flow of $19.82 Million. Check ABCL cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

1.89x
(Capex + Investments) / Operating CF

Total Reinvested

$37.52 Million
Capex + Investments

Operating Cash Flow

$19.82 Million
USD

Capital Expenditures

$27.35 Million
USD

Abcellera Biologics Inc Cash Flow Reinvestment Rate (2018–2022)

Historical reinvestment intensity for Abcellera Biologics Inc across 5 annual periods. Explore long-term investment intensity of Abcellera Biologics Inc to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for Abcellera Biologics Inc (2018–2022)

Year-by-year capital reinvestment analysis for Abcellera Biologics Inc. For live market cap and broader valuation context, see how much is Abcellera Biologics Inc worth.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2022 1.53x $425.29 Million $277.36 Million $72.66 Million ▲ +11.7%
2021 1.37x $335.88 Million $244.58 Million $58.45 Million ▼ -8.1%
2020 1.49x $33.92 Million $22.69 Million $14.67 Million ▼ -58.8%
2019 3.63x $9.78 Million $2.69 Million $4.00 Million ▲ +21.9%
2018 2.98x $10.61 Million $3.56 Million $5.31 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow